BIO Comments to FDA on Manufacturing Changes and Comparability for Human Cellular and Gene Therapy Products
October 27, 2023
BIO submits comments and specific recommendations to the U.S. Food and Drug Administration on their Draft Guidance for Industry (Docket No. FDA-2023-D-2436)
BIO submits comments and specific recommendations to the U.S. Food and Drug Administration on their Draft Guidance for Industry (Docket No. FDA-2023-D-2436)